Share on StockTwits

Vertex Pharmaceuticals (NASDAQ:VRTX) EVP Peter Mueller sold 7,500 shares of Vertex Pharmaceuticals stock on the open market in a transaction dated Monday, June 16th. The shares were sold at an average price of $68.31, for a total value of $512,325.00. Following the sale, the executive vice president now directly owns 143,517 shares in the company, valued at approximately $9,803,646. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Vertex Pharmaceuticals (NASDAQ:VRTX) traded down 1.23% during mid-day trading on Wednesday, hitting $65.08. 2,213,199 shares of the company’s stock traded hands. Vertex Pharmaceuticals has a 52-week low of $58.06 and a 52-week high of $89.96. The stock’s 50-day moving average is $69.48 and its 200-day moving average is $73.31. The company’s market cap is $15.372 billion.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings data on Thursday, May 1st. The company reported ($0.65) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.68) by $0.03. The company had revenue of $118.50 million for the quarter, compared to the consensus estimate of $134.46 million. During the same quarter last year, the company posted $0.03 earnings per share. Vertex Pharmaceuticals’s revenue was down 63.9% compared to the same quarter last year. On average, analysts predict that Vertex Pharmaceuticals will post $-2.82 earnings per share for the current fiscal year.

A number of analysts have recently weighed in on VRTX shares. Analysts at HC Wainwright reiterated a “buy” rating on shares of Vertex Pharmaceuticals in a research note on Thursday, June 5th. Separately, analysts at Zacks downgraded shares of Vertex Pharmaceuticals from an “outperform” rating to a “neutral” rating in a research note on Wednesday, May 21st. They now have a $72.30 price target on the stock. Finally, analysts at TheStreet downgraded shares of Vertex Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, May 6th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and seven have assigned a buy rating to the stock. The company presently has an average rating of “Hold” and an average target price of $88.14.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is in the business of discovering, developing, manufacturing and commercializing small molecule drugs for the treatment of serious diseases.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.